Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

Bristish Study Celexa in MDD at Doses Up to 50mg

Posted by Phillipa on June 6, 2012, at 18:40:18

Seems a study in England used celexa generic for MDD in doses up to 50mg. Some did achive remission. Phillipa

From BMC Psychiatry

Efficacy, Safety and Tolerability of Escitalopram in Doses up to 50 mg in Major Depressive Disorder (MDD)

Alan G Wade, MBChB; Gordon M Crawford, MBChB; Ann Yellowlees, PhD

Authors and Disclosures

Posted: 04/21/2011; BMC Psychiatry. 2011;11 © 2011 BioMed Central, Ltd.





Abstract and Introduction
Background
Methods
Results
Discussion
Conclusions
References


Abstract and Introduction

Abstract

Background Escitalopram is licensed for use at doses up to 20 mg but is used clinically at higher doses. There is limited published data at higher doses and none in the treatment of Major Depressive Disorder (MDD).
Methods This open-label, pilot study was designed to investigate the efficacy, safety and tolerability of escitalopram in doses up to 50 mg in MDD. It was conducted in 60 primary care patients with MDD who had not responded to adequate treatment with citalopram. Patients were treated with escalating doses of escitalopram up to 50 mg for up to 32 weeks until they achieved remission (MontgomeryAsberg Depression Rating Scale [MADRS] ≤8) or failed to tolerate the dose.
Results Forty-two patients (70%) completed the study. Twenty-one patients (35%) achieved remission with 8 of the 21 patients (38%) needing the 50 mg dose to achieve remission. Median time to remission was 24 weeks and median dose in remission was 30 mg. No significant safety issues were identified although tolerability appeared to decline above a dose of 40 mg with 26% of patients unable to tolerate 50 mg. Twelve (20%) patients had adverse events leading to discontinuation. The most common adverse events were headache (35%), nausea, diarrhoea and nasopharyngitis (all 25%). Minor mean weight gain was found during the study, which did not appear to be dose-related. Half of the patients who completed the study chose to continue treatment with escitalopram rather than taper down the dose at 32 weeks.
Conclusions Dose escalation with escitalopram above 20 mg may have a useful role in the management of patients with MDD, although further studies are needed to confirm this finding.


Section 1 of 6

 

Thread

 

Post a new follow-up

Your message only Include above post


Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.

 

Start a new thread

 
Google
dr-bob.org www
Search options and examples
[amazon] for
in

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:Phillipa thread:1019344
URL: http://www.dr-bob.org/babble/20120522/msgs/1019344.html